Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.
Ter Heine R, van den Heuvel MM, Piet B, Deenen MJ, van der Wekken AJ, Hendriks LEL, Croes S, van Geel RMJM, Jansman FGA, Boshuizen RC, Franssen EJF, Smit AAJ, Dumoulin DW, Oude Munnink TH, Smit EF, Derijks HJ, van der Leest CH, Hendrikx JJMA, Moes DJAR, de Rouw N. Ter Heine R, et al. Among authors: van geel rmjm. Target Oncol. 2023 May;18(3):441-450. doi: 10.1007/s11523-023-00958-6. Epub 2023 Apr 21. Target Oncol. 2023. PMID: 37081309 Free PMC article.
Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
van Veelen A, Veerman GDM, Verschueren MV, Gulikers JL, Steendam CMJ, Brouns AJWM, Dursun S, Paats MS, Tjan-Heijnen VCG, van der Leest C, Dingemans AC, Mathijssen RHJ, van de Garde EMW, Souverein P, Driessen JHM, Hendriks LEL, van Geel RMJM, Croes S. van Veelen A, et al. Among authors: van geel rmjm. Int J Cancer. 2024 Jan 15;154(2):332-342. doi: 10.1002/ijc.34742. Epub 2023 Oct 15. Int J Cancer. 2024. PMID: 37840304
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC.
Gulikers JL, Veerman GDM, Jebbink M, Kruithof PD, Steendam CMJ, Boosman RJ, Mathijssen RHJ, Tjan-Heijnen VCG, Driessen JHM, Dursun S, Smit EF, Dingemans AC, van Geel RMJM, Croes S, Hendriks LEL. Gulikers JL, et al. Among authors: van geel rmjm. JTO Clin Res Rep. 2024 Feb 20;5(4):100656. doi: 10.1016/j.jtocrr.2024.100656. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38550297 Free PMC article.
Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.
Gulikers JL, Otten LS, Hendriks LEL, Winckers K, Henskens Y, Leentjens J, van den Heuvel MM, Ter Heine R, Croes S, Piet B, van Geel RMJM. Gulikers JL, et al. Among authors: van geel rmjm. Br J Cancer. 2024 Aug;131(3):481-490. doi: 10.1038/s41416-024-02744-1. Epub 2024 Jun 11. Br J Cancer. 2024. PMID: 38862741 Free PMC article.
Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs.
Kruithof PD, de Beer YM, Gulikers JL, Stolk LML, Hendriks LEL, Croes S, van Geel RMJM. Kruithof PD, et al. Among authors: van geel rmjm. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Dec 1;1231:123918. doi: 10.1016/j.jchromb.2023.123918. Epub 2023 Nov 7. J Chromatogr B Analyt Technol Biomed Life Sci. 2023. PMID: 37979367 Free article.
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Huijberts SCFA, van Geel RMJM, van Brummelen EMJ, Opdam FL, Marchetti S, Steeghs N, Pulleman S, Thijssen B, Rosing H, Monkhorst K, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. Huijberts SCFA, et al. Among authors: van brummelen emj, van geel rmjm. Cancer Chemother Pharmacol. 2020 May;85(5):917-930. doi: 10.1007/s00280-020-04066-4. Epub 2020 Apr 9. Cancer Chemother Pharmacol. 2020. PMID: 32274564 Clinical Trial.
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.
Otten LS, Piet B, van den Heuvel MM, Marzolini C, van Geel RMJM, Gulikers JL, Burger DM, Leentjens J, Ter Heine R. Otten LS, et al. Among authors: van geel rmjm. Eur Respir Rev. 2022 Jun 14;31(164):220004. doi: 10.1183/16000617.0004-2022. Print 2022 Jun 30. Eur Respir Rev. 2022. PMID: 35705208 Free PMC article. Review.
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, de Vos FYFL, Lolkema MPJK, Devriese LA, Opdam FL, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. van Geel RMJM, et al. Among authors: van brummelen emj. Br J Cancer. 2020 Apr;122(8):1166-1174. doi: 10.1038/s41416-020-0776-z. Epub 2020 Mar 9. Br J Cancer. 2020. PMID: 32147669 Free PMC article. Clinical Trial.
23 results